As part of the changed license, BioTime is now licensed globally for all uses, excluding veterinary medicine and animal health.
The extended field of use includes human pharmaceutical and medical device applications, tissue engineering and regenerative medicine uses and also research applications.
BioTime chief commercial officer William Tew said BioTime is pleased to have license to the full spectrum of human medical products possible with HyStem.
"In addition to Renevia™ which is currently in preclinical studies, we have initiated development programs for additional products that are planned as relatively near-term sources of revenue while strategically laying the foundation for the wide array of cell-based regenerative therapies that may be developed based on stem cell sciences," Tew added.